Asunto(s)
Fármacos Anti-VIH , Infecciones por VIH , Cumplimiento de la Medicación , Profilaxis Pre-Exposición , Humanos , Infecciones por VIH/prevención & control , Infecciones por VIH/orina , Profilaxis Pre-Exposición/métodos , Profilaxis Pre-Exposición/economía , Fármacos Anti-VIH/uso terapéutico , Sistemas de Atención de Punto , Pruebas en el Punto de Atención/economía , Masculino , Urinálisis/métodos , Urinálisis/economíaRESUMEN
Importance: The evidence for and against screening for chronic kidney disease in youths who are asymptomatic is inconsistent worldwide. Japan has been conducting urinary screening in students for 50 years, allowing for a full economic evaluation that includes the clinical benefits of early detection and intervention for chronic kidney disease. Objectives: To evaluate the clinical effectiveness and cost-effectiveness of school urinary screening in Japan, with a focus on the benefits of the early detection and intervention for IgA nephropathy, and to explore key points in the model that are associated with the cost-effectiveness of the school urinary screening program. Design, Setting, and Participants: This economic evaluation with a cost-effectiveness analysis used a computer-simulated Markov model from the health care payer's perspective among a hypothetical cohort of 1â¯000â¯000 youths aged 6 years in first grade in Japanese elementary schools, followed up through junior and high school. The time horizon was lifetime. Costs and clinical outcomes were discounted at a rate of 2% per year. Costs were calculated in Japanese yen and 2020 US dollars (¥107 = US $1). Interventions: School urinary screening for IgA nephropathy was compared with no screening. Main Outcomes and Measures: Outcomes were costs and quality-adjusted life-years (QALYs). Cost-effectiveness was determined by evaluating whether the incremental cost-effectiveness ratio (ICER) per QALY gained remained less than ¥7â¯500â¯000 (US $70â¯093). Results: In the base case analysis, the ICER was ¥4â¯186â¯642 (US $39â¯127)/QALY, which was less than the threshold. There were 60.3 patients/1â¯000â¯000 patients in the no-screening strategy and 31.7 patients/1â¯000â¯000 patients in the screening strategy with an end-stage kidney disease. Cost-effectiveness improved as the number of screenings decreased (screening frequency <3 times: incremental cost, -¥75 [US $0.7]; incremental QALY, 0.00025; ICER, dominant), but the number of patients with end-stage kidney disease due to IgA nephropathy increased (40.9 patients/1â¯000â¯000 patients). Assuming the disutility due to false positives had a significant impact on the analysis; assuming a disutility of 0.01 or more, the population with no IgA nephropathy had an ICER greater than the threshold (¥8â¯304â¯093 [US $77â¯608]/QALY). Conclusions and Relevance: This study found that Japanese school urinary screening was cost-effective, suggesting that it may be worthy of resource allocation. Key factors associated with cost-effectiveness were screening cost, the probability of incident detection outside of screening, and IgA nephropathy incidence, which may provide clues to decision-makers in other countries when evaluating the program in their own context.
Asunto(s)
Glomerulonefritis por IGA , Adolescente , Humanos , Análisis de Costo-Efectividad , Glomerulonefritis por IGA/diagnóstico , Glomerulonefritis por IGA/orina , Japón , Fallo Renal Crónico/diagnóstico , Fallo Renal Crónico/orina , Insuficiencia Renal Crónica/diagnóstico , Insuficiencia Renal Crónica/orina , Urinálisis/economíaAsunto(s)
Antibacterianos , Atención de Bajo Valor , Uso Excesivo de los Servicios de Salud , Cuidados Preoperatorios , Utilización de Procedimientos y Técnicas , Urinálisis , Enfermedades Urológicas , Adulto , Antibacterianos/economía , Antibacterianos/uso terapéutico , Enfermedades Transmisibles/diagnóstico , Enfermedades Transmisibles/epidemiología , Farmacorresistencia Microbiana/efectos de los fármacos , Femenino , Adhesión a Directriz/estadística & datos numéricos , Humanos , Masculino , Uso Excesivo de los Servicios de Salud/economía , Uso Excesivo de los Servicios de Salud/prevención & control , Guías de Práctica Clínica como Asunto , Cuidados Preoperatorios/métodos , Cuidados Preoperatorios/normas , Cuidados Preoperatorios/estadística & datos numéricos , Prevalencia , Utilización de Procedimientos y Técnicas/economía , Utilización de Procedimientos y Técnicas/estadística & datos numéricos , Estados Unidos/epidemiología , Urinálisis/economía , Urinálisis/métodos , Urinálisis/estadística & datos numéricos , Enfermedades Urológicas/epidemiología , Enfermedades Urológicas/terapia , Enfermedades Urológicas/orinaRESUMEN
Currently, most HIV tests are performed with blood samples, or alternatively saliva samples are used for HIV testing. Simple HIV tests need to be performed in hospitals or other medical agencies instead of more invasive HIV blood tests. To enable point-of-care (POC) HIV diagnostics, based on a recently developed lateral flow strip for HIV urine testing, a microfluidic immunoassay cassette with a handheld optical reader is developed. Based on lateral flow strip with gold colloid reporter, the integrated immunoassay cassette can perform sample introduction, metering, discharging, applying and detection which simplifies HIV testing. An indicator is incorporated into the cassette to guide sample introduction based on color change, and further, the excess test sample is stored inside the sealed cassette to avoid any contamination. The low-cost handheld optical reader can provide a test result within a few seconds, which is useful for simple, sensitive and affordable HIV onsite detection. Instead of using normal white LEDs, a customized back light module embedded with green LEDs is adopted to illuminate the lateral flow strip with an appropriate working current to achieve optimal performance. Compared to the standard lateral flow strips using a benchtop reader, with the disposable immunoassay cassette assisted by the handheld optical reader, more convenient, easier-to-operate, and more affordable HIV urine testing can be achieved in POC diagnostics.
Asunto(s)
Infecciones por VIH/orina , Inmunoensayo/instrumentación , Pruebas en el Punto de Atención , Urinálisis/instrumentación , Costos y Análisis de Costo , Infecciones por VIH/diagnóstico , Humanos , Inmunoensayo/economía , Urinálisis/clasificación , Urinálisis/economíaRESUMEN
AIM: The urine dipstick is a simple diagnostic module for detecting proteinuria, haematuria and glycosuria and is favourably accepted in East Asia despite debates regarding its accuracy and target population, claiming that quantitative tests for a high-risk cohort should be more cost-effective. However, the current status of utilizing this test in these countries is not widely known due to lack of extensive data. We aimed to clarify the current nationwide and regional status of utilization of the urine dipstick test in an outpatient care setting and to determine the regional factors associated with adoption of this method. METHODS: This cross-sectional study used openly accessible data from the national claim database that included the health insurance claims data of the Japanese population in 2017. RESULTS: In total, 67 125 386 urine dipstick tests were performed compared with 1 862 700 quantitative urine protein tests and 17 544 949 urine sediment microscopy tests. Dipstick tests were employed principally for those who are >65 years old (60.3%) and, although the male population (52.5%) is generally larger, the female population is larger in age of 15 to 39 years and >85 years. Multivariate analysis with several regional parameters revealed that the test was performed more commonly in the areas that accommodate greater elderly population (P < .01). CONCLUSION: Despite a heated dispute, the urine dipstick test is performed even more frequently than the quantitative biochemical or microscopic sediment tests, especially in regions holding the larger elderly population, which suggests that the test forms a part of geriatric medical care.
Asunto(s)
Atención Ambulatoria , Glucosuria/diagnóstico , Hematuria/diagnóstico , Proteinuria/diagnóstico , Tiras Reactivas , Insuficiencia Renal Crónica , Urinálisis , Adolescente , Adulto , Factores de Edad , Anciano de 80 o más Años , Atención Ambulatoria/economía , Atención Ambulatoria/métodos , Atención Ambulatoria/estadística & datos numéricos , Análisis Costo-Beneficio , Estudios Transversales , Femenino , Glucosuria/etiología , Hematuria/etiología , Humanos , Japón/epidemiología , Masculino , Utilización de Procedimientos y Técnicas , Proteinuria/etiología , Insuficiencia Renal Crónica/complicaciones , Insuficiencia Renal Crónica/diagnóstico , Insuficiencia Renal Crónica/epidemiología , Insuficiencia Renal Crónica/psicología , Urinálisis/economía , Urinálisis/métodosRESUMEN
BACKGROUND: Rapid and accurate diagnosis of mucopolysaccharidoses (MPS) is still a challenge due to poor access to screening and diagnostic methods and to their extensive clinical heterogeneity. The aim of this work is to perform laboratory biochemical testing for confirming the diagnosis of mucopolysaccharidosis (MPS) for the first time in Morocco. METHODS: Over a period of twelve months, 88 patients suspected of having Mucopolysaccharidosis (MPS) were referred to our laboratory. Quantitative and qualitative urine glycosaminoglycan (GAG) analyses were performed, and enzyme activity was assayed on dried blood spots (DBS) using fluorogenic substrates. Enzyme activity was measured as normal, low, or undetectable. RESULTS: Of the 88 patients studied, 26 were confirmed to have MPS; 19 MPS I (Hurler syndrome; OMIM #607014/Hurler-Scheie syndrome; OMIM #607015), 2 MPS II (Hunter syndrome; OMIM #309900), 2 MPS IIIA (Sanfilippo syndrome; OMIM #252900), 1 MPS IIIB (Sanfilippo syndrome; OMIM #252920) and 2 MPS VI (Maroteaux-Lamy syndrome; OMIM #253200). Parental consanguinity was present in 80.76% of cases. Qualitative urinary glycosaminoglycan (uGAGs) assays showed abnormal profiles in 31 cases, and further quantitative urinary GAG evaluation and Thin Layer Chromatography (TLC) provided important additional information about the likely MPS diagnosis. The final diagnosis was confirmed by specific enzyme activity analysis in the DBS samples. CONCLUSIONS: The present study shows that the adoption of combined urinary substrate analysis and enzyme assays using dried blood spots can facilitate such diagnosis, offer an important tool for an appropriate supporting care, and a specific therapy, when available.
Asunto(s)
Mucopolisacaridosis/diagnóstico , Mucopolisacaridosis/orina , Urinálisis , Adolescente , Arilsulfatasas/metabolismo , Arilsulfatasas/orina , Niño , Preescolar , Cromatografía en Capa Delgada , Pruebas con Sangre Seca/economía , Pruebas con Sangre Seca/métodos , Femenino , Glicosaminoglicanos/análisis , Glicosaminoglicanos/metabolismo , Humanos , Iduronidasa/metabolismo , Iduronidasa/orina , Masculino , Marruecos , Mucopolisacaridosis/enzimología , Mucopolisacaridosis/metabolismo , Proyectos Piloto , Urinálisis/economía , Urinálisis/métodosRESUMEN
OBJECTIVES: Diabetes is a global epidemic, and the high cost of annually and quantitatively measuring urine albumin excretion using the turbidimetric immunoassay is challenging. We aimed to determine whether a semi-quantitative urinary albumin-creatinine ratio test could be used as a screening tool for microalbuminuria in diabetic patients. METHODS: We assessed the diagnostic accuracy of the semi-quantitative method. The costs of false results in the semi-quantitative method were calculated based on the annual probability of disease progression analyzed through a systematic literature review and meta-analysis. The pooled long-term cost-saving effect of the semi-quantitative method compared with the quantitative test was assessed using a Markov model simulating a long-term clinical setting. Diagnostic accuracy and the cost-saving effect were also validated in an independent external cohort. RESULTS: Compared with the quantitative test, the semi-quantitative method had sensitivities of 93.5% and 81.3% and specificities of 61.4% and 63.1% in the overall sample of diabetic patients (n = 1,881) and in diabetic patients with eGFR ≥60 ml/min/1.73 m2 and a negative dipstick test (n = 1,110), respectively. After adjusting for direct and indirect medical costs, including the risk of disease progression, which was adjusted by the meta-analyzed hazard ratio for clinical outcomes, it was determined that using the semi-quantitative method could save 439.4 USD per person for 10 years. Even after adjusting the result to the external validation cohort, 339.6 USD could be saved for one diabetic patient for 10 years. CONCLUSIONS: The semi-quantitative method could be an appropriate screening tool for albuminuria in diabetic patients. Moreover, it can minimize the testing time and inconvenience and significantly reduce national health costs.
Asunto(s)
Albuminuria/diagnóstico , Diabetes Mellitus/orina , Nefropatías Diabéticas/diagnóstico , Nefropatías Diabéticas/orina , Tamizaje Masivo/métodos , Urinálisis/métodos , Albuminuria/orina , Estudios de Cohortes , Ahorro de Costo/estadística & datos numéricos , Humanos , Tamizaje Masivo/economía , Reproducibilidad de los Resultados , República de Corea , Urinálisis/economía , Urinálisis/estadística & datos numéricosAsunto(s)
Atención Ambulatoria/estadística & datos numéricos , Dermatología/estadística & datos numéricos , Atención Primaria de Salud/estadística & datos numéricos , Brechas de la Práctica Profesional/estadística & datos numéricos , Vasculitis Leucocitoclástica Cutánea/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Atención Ambulatoria/economía , Atención Ambulatoria/organización & administración , Biopsia/economía , Biopsia/estadística & datos numéricos , Dermatología/economía , Dermatología/organización & administración , Femenino , Gastos en Salud/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Atención Primaria de Salud/economía , Atención Primaria de Salud/organización & administración , Brechas de la Práctica Profesional/economía , Brechas de la Práctica Profesional/organización & administración , Piel/irrigación sanguínea , Piel/patología , Urinálisis/economía , Urinálisis/estadística & datos numéricos , Vasculitis Leucocitoclástica Cutánea/economía , Vasculitis Leucocitoclástica Cutánea/patología , Vasculitis Leucocitoclástica Cutánea/orina , Adulto JovenRESUMEN
BACKGROUND: People with diabetes are at increased risk of developing chronic kidney disease (CKD) and should undergo annual screening, but adherence is poor. A home urinalysis self-test has been developed to improve compliance with screening. The objective of this paper is to report on a clinical evaluation and economic analysis of home urinalysis self-testing. RESEARCH DESIGN AND METHODS: People with diabetes who had not undergone screening within the previous 18 months were recruited to a single-arm clinical evaluation to assess the uptake and compliance of home urinalysis self-testing. An economic evaluation assessed the likely cost-consequences of the use of home urinalysis self-testing over a lifetime time horizon. RESULTS: A total of 2,196 people with diabetes were contacted as part of the clinical evaluation. Of these, 695 people agreed to be sent a home urinalysis self-testing kit and 499 people completed and returned the test. Cost savings of £2,008 per person were estimated over a lifetime due to increased CKD diagnosis and reduced progression to end stage renal disease. CONCLUSIONS: Home urinalysis self-testing of ACR in people with diabetes is estimated to be a cost-effective use of NHS resources in England in people who would otherwise not comply with standard care.
Asunto(s)
Diabetes Mellitus/orina , Cooperación del Paciente , Teléfono Inteligente , Urinálisis/métodos , Albuminuria/diagnóstico , Ahorro de Costo , Análisis Costo-Beneficio , Progresión de la Enfermedad , Inglaterra , Humanos , Fallo Renal Crónico/etiología , Fallo Renal Crónico/prevención & control , Tamizaje Masivo/economía , Tamizaje Masivo/métodos , Insuficiencia Renal Crónica/etiología , Insuficiencia Renal Crónica/prevención & control , Autoevaluación , Urinálisis/economíaRESUMEN
INTRODUCTION: Italian law mandates that every competitive athlete must undergo annual preparticipation evaluation (PPE) to identify cardiovascular (CV) diseases that pose a risk of sudden death (SD) during sport and other conditions that may threaten the athlete's health. We investigated the diagnostic yield, rate of disqualification and costs of our PPE. METHODS: We included 5910 consecutive apparently healthy athletes (61% males, mean age 15±4 years) who underwent annual PPE performed by a sports medicine specialist. The PPE included history, physical examination, weight, height and blood pressure measurement, test of visual acuity, spirometry, urine chemistry, resting 12-lead ECG and exercise testing with ECG monitoring. In cases of abnormal findings, we carried out second-line investigations. RESULTS: During a 12-month study period, 5.326 (90.2%) athletes were cleared for competition after a normal first-line evaluation and 584 (9.8%) underwent one or more further examinations. Of those, 88 (1.5%) were diagnosed to have a CV disease (including 18 (0.3%) at-risk of SD) and 31 (0.5%) had a non-CV diagnosis. A total of 32 (0.5%) athletes were temporarily (n=15) or permanently (n=17) disqualified from competitive sports. The average cost per athlete was 79, which consisted of 64 (80%) for first-line evaluations and 15 (20%) for additional investigations. CONCLUSION: PPE according to the Italian model identified a range of diseases in 2.0% of apparently healthy athletes at an average cost of 79.
Asunto(s)
Enfermedades Cardiovasculares/diagnóstico , Costos y Análisis de Costo , Muerte Súbita Cardíaca/prevención & control , Prueba de Esfuerzo/economía , Examen Físico/economía , Deportes/economía , Adolescente , Adulto , Niño , Femenino , Humanos , Italia , Masculino , Persona de Mediana Edad , Espirometría/economía , Urinálisis/economía , Pruebas de Visión/economía , Adulto JovenRESUMEN
AIM: Unnecessary treatment of asymptomatic bacteriuria is a concern. Hutt Valley District Health Board sought to reduce clinically inappropriate urine culture requests through removal of urine dipsticks from wards and education of staff using Choosing Wisely principles. The purpose of this research is to quantitatively evaluate the success of these initiatives. METHODS: The numbers and results of urine cultures performed for Hutt Valley DHB were analysed, for the period from January 2015 to October 2017. Urinalyses were compared between those designated as 'inpatient' and those as 'outpatient', with the latter being the control of this study. The numbers of primary and secondary coded discharge diagnoses of UTIs were used as a measure of the negative impact of the interventions. RESULTS: There was a 28% reduction in monthly urine culture requests for inpatients, after staff education and removal of urine dipsticks, with no change in those for outpatients (the negative control). After the intervention, a higher proportion of urine cultures were positive for urinary pathogens (25.2% compared to 23.0%) and the average number of diagnoses of UTI in hospital discharges decreased 17% (from 161 to 134). CONCLUSION: The removal of urine dipsticks from wards and the education of staff significantly reduced the number of urine culture requests and is a useful strategy to reduce the overuse of antibiotics for asymptomatic bacteriuria without an increase in the number of UTIs. These simple interventions could be used at other hospitals as part of measures to reduce unnecessary care and overdiagnosis.
Asunto(s)
Uso Excesivo de los Servicios de Salud/prevención & control , Procedimientos Innecesarios/estadística & datos numéricos , Urinálisis/estadística & datos numéricos , Adulto , Educación en Salud , Humanos , Uso Excesivo de los Servicios de Salud/economía , Uso Excesivo de los Servicios de Salud/estadística & datos numéricos , Nueva Zelanda , Procedimientos Innecesarios/economía , Urinálisis/economía , Urinálisis/métodos , Infecciones Urinarias/diagnóstico , Infecciones Urinarias/microbiologíaRESUMEN
AIM: Hypertension is a public health problem managed according to therapeutic strategies published in France by the Hauteautoritéde santé (HAS - French Health Authorities). For patients with resistant hypertension, related or not to a non-adherence, prescribers need to be sure the exposure is high enough to achieve the tensional target. Quantitative analysis of antihypertensive drugs in different biological matrices (blood/urine) is one possible solution. However, this involves determining the concentrations observed at standard doses and knowing how to interpret the measured concentrations. It is also necessary to identify medical laboratories that can assay antihypertensive drugs. This was the aim of our work. METHODS: The main antihypertensive drugs recommended by the HAS have been listed. For each of them, we looked for published steady-state plasma/serum concentrations and quantities excreted in the urine at usual dosages. In addition, the elimination half-life and linear pharmacokinetic profile were specified for each antihypertensive agent measured in plasma/serum. Pharmacology-Toxicology laboratories in France likely to carry out assays were identified. The time taken to report the result and the cost of the analysis were also specified. RESULTS: All of the afore-mentioned information has been collected and presented in a table. This can then be used to compare the plasma/serum concentration or the quantity measured in a patient's urine with the values reported in the literature. In cases where the blood sampling times differ between those of the patient and the published data, the patient's measured value is compared to the estimated value based on the published concentrations and pharmacokinetics. CONCLUSION: Interpretation of the plasma/serum/urinary value measured or estimated for an antihypertensive drug is a particularly interesting approach to determine if drug exposure is enough and a possible non-adherence. However, this activity is mostly carried out in hospital centres.
Asunto(s)
Antihipertensivos/farmacocinética , Antihipertensivos/uso terapéutico , Técnicas de Laboratorio Clínico/métodos , Monitoreo de Drogas/métodos , Hipertensión/tratamiento farmacológico , Antihipertensivos/análisis , Antihipertensivos/economía , Disponibilidad Biológica , Análisis Químico de la Sangre/economía , Análisis Químico de la Sangre/métodos , Servicios de Laboratorio Clínico/economía , Técnicas de Laboratorio Clínico/economía , Costos y Análisis de Costo , Relación Dosis-Respuesta a Droga , Monitoreo de Drogas/economía , Francia/epidemiología , Humanos , Hipertensión/epidemiología , Hipertensión/metabolismo , Cumplimiento de la Medicación , Planificación de Atención al Paciente , Urinálisis/economía , Urinálisis/métodosRESUMEN
Purpose: To evaluate the budget impact of adding a diagnostic test of tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 ([TIMP-2]·[IGFBP7]), which identifies patients at risk of moderate-to-severe acute kidney injury (AKI), to the current standard of care (SOC) in a hospital setting.Materials and methods: A budget impact model (2017 USD) was developed from the perspective of a hypothetical US hospital system serving 10,000 inpatients annually. The model estimated the impact of assessing the risk of AKI using SOC vs a combination of SOC and the US Food and Drug Administration-approved assay [TIMP-2]·[IGFBP7] over a 1-year period. Potential cost implications were assessed using estimates for payer mix among patients, diagnostic efficacy, and patient healthcare resource utilization. The model also considered provider adoption rates and the estimated costs of [TIMP-2]·[IGFBP7].Results: Compared to SOC alone, adding [TIMP-2]·[IGFBP7] to SOC was associated with a $1,855 reduction in uncompensated care per patient tested, which, after accounting for the additional costs of the test ($277), resulted in net savings of $1,578 per patient tested. The findings were robust to input parameter variations, as demonstrated by deterministic and probabilistic sensitivity analyses. In the probabilistic sensitivity analyses, net cost savings to the hospital ranged from $50,308-$3,971,514, or $101-$7,943 per tested patient (mean = $1,710; 95% confidence interval = $1,691-$1,729).Conclusions: The introduction of [TIMP-2]·[IGFBP7] as a novel tool in the identification of AKI risk may result in considerable cost savings from a hospital perspective under this model's base-case assumptions. Further prospective studies are needed to confirm these findings in a real-world setting.Key points for decision makersAn economic model was constructed to determine the budget impact of adding a diagnostic test ([TIMP-2]·[IGFBP7]), which identifies patients at risk of moderate-to-severe acute kidney injury, to the current standard of care (SOC) in a hospital setting.According to the present model, the use of [TIMP-2]·[IGFBP7] to identify acute kidney injury risk may reduce costs for hospitals by â¼$1,578 per patient tested.
Asunto(s)
Lesión Renal Aguda/diagnóstico , Proteínas de Unión a Factor de Crecimiento Similar a la Insulina/orina , Inhibidor Tisular de Metaloproteinasa-2/orina , Urinálisis/economía , Biomarcadores , Análisis Costo-Beneficio , Diagnóstico Precoz , Gastos en Salud/estadística & datos numéricos , Recursos en Salud/economía , Servicios de Salud/economía , Humanos , Estudios Prospectivos , Curva ROC , Medición de Riesgo , Sensibilidad y Especificidad , Índice de Severidad de la EnfermedadRESUMEN
BACKGROUND: Current guidelines recommend the use of the lateral flow urine lipoarabinomannan assay (LAM) in HIV-positive, ambulatory patients with signs and symptoms of tuberculosis (TB) only if they are seriously ill or have CD4 count ≤ 100 cells/µl. We assessed the diagnostic yield of including LAM in TB diagnostic algorithms in HIV-positive, ambulatory patients with CD4 < 200 cells/µl, as well as the risk of mortality in LAM-positive patients who were not diagnosed using other diagnostic tools and not treated for TB. METHODS AND FINDINGS: We conducted a prospective observational study including HIV-positive adult patients with signs and symptoms of TB and CD4 < 200 cells/µl attending 6 health facilities in Malawi and Mozambique. Patients were included consecutively from 18 September 2015 to 27 October 2016 in Malawi and from 3 December 2014 to 22 August 2016 in Mozambique. All patients had a clinical exam and LAM, chest X-ray, sputum microscopy, and Xpert MTB/RIF assay (Xpert) requested. Culture in sputum was done for a subset of patients. The diagnostic yield was defined as the proportion of patients with a positive assay result among those with laboratory-confirmed TB. For the 456 patients included in the study, the median age was 36 years (IQR 31-43) and the median CD4 count was 50 cells/µl (IQR 21-108). Forty-five percent (205/456) of the patients had laboratory-confirmed TB. The diagnostic yields of LAM, microscopy, and Xpert were 82.4% (169/205), 33.7% (69/205), and 40.0% (84/205), respectively. In total, 50.2% (103/205) of the patients with laboratory-confirmed TB were diagnosed only through LAM. Overall, the use of LAM in diagnostic algorithms increased the yield of algorithms with microscopy and with Xpert by 38.0% (78/205) and 34.6% (71/205), respectively, and, specifically among patients with CD4 100-199 cells/µl, by 27.5% (14/51) and 29.4% (15/51), respectively. LAM-positive patients not diagnosed through other tools and not treated for TB had a significantly higher risk of mortality than LAM-positive patients who received treatment (adjusted risk ratio 2.57, 95% CI 1.27-5.19, p = 0.009). Although the TB diagnostic conditions in the study sites were similar to those in other resource-limited settings, the added value of LAM may depend on the availability of microscopy or Xpert results. CONCLUSIONS: LAM has diagnostic value for identifying TB in HIV-positive patients with signs and symptoms of TB and advanced immunodeficiency, including those with a CD4 count of 100-199 cells/µl. In this study, the use of LAM enabled the diagnosis of TB in half of the patients with confirmed TB disease; without LAM, these patients would have been missed. The rapid identification and treatment of TB enabled by LAM may decrease overall mortality risk for these patients.
Asunto(s)
Infecciones por VIH/orina , Seropositividad para VIH/orina , Lipopolisacáridos/orina , Tuberculosis/diagnóstico , Adulto , Instituciones de Atención Ambulatoria , Recuento de Linfocito CD4 , Coinfección/diagnóstico , Coinfección/orina , Femenino , Infecciones por VIH/sangre , Infecciones por VIH/complicaciones , Infecciones por VIH/diagnóstico , Seropositividad para VIH/sangre , Seropositividad para VIH/complicaciones , Recursos en Salud , Humanos , Malaui , Masculino , Mozambique , Sistemas de Atención de Punto , Áreas de Pobreza , Valor Predictivo de las Pruebas , Sensibilidad y Especificidad , Tuberculosis/sangre , Tuberculosis/complicaciones , Tuberculosis/orina , Urinálisis/economía , Urinálisis/métodosRESUMEN
BACKGROUND: Empiric therapy for urinary tract infection is difficult in postmenopausal women because of the higher rates of confounding lower urinary tract symptoms and differential resistance profiles of uropathogens in this population. OBJECTIVE: The objective of the study was to determine the least costly strategy for treatment of postmenopausal women with the primary complaint of dysuria. STUDY DESIGN: We performed a cost minimization analysis modeling the following clinical options: (1) empiric antibiotic therapy followed by urine culture, (2) urinalysis with empiric antibiotic therapy only if positive nitrites and leukocyte esterase, or (3) waiting for culture prior to initiating antibiotics. For all strategies we included nitrofurantoin, trimethoprim/sulfamethoxazole, fosfomycin, ciprofloxacin, or cephalexin. Pathogens included Escherichia coli, Enterococcus faecalis, Klebsiella pneumonaie, or Proteus mirabalis. Pathogens, resistance, treatment success, and medication side effects were specific to postmenopausal women. RESULTS: Cost minimization modeling with TreeAge Pro assumed 73.4% of urinary tract infections were caused by Escherichia coli with 24.4% resistance to nitrofurantoin, trimethoprim/sulfamethoxazole. With our assumptions, empiric antibiotics with nitrofurantoin, trimethoprim/sulfamethoxazole was the least costly approach ($89.64/patient), followed by waiting for urine culture ($97.04/patient). Except for empiric antibiotics with fosfomcyin, empiric antibiotics was always less costly than using urinalysis to discriminate antibiotic use. This is due to the cost of urinalysis ($38.23), high rate of both urinary tract infection (91%), and positive urinalysis (69.3%) with dysuria in postmenopausal women and resultant high rate of antibiotic use with or without urinalysis. Options with fosfomycin were the most expensive because of the highest drug costs ($98/dose), and tornado analyses showed fosfomycin cost was the most impactful variable for model outcomes. Sensitivity analyses showed empiric fosfomycin became the least costly option if drug costs were $25.80, a price still more costly than almost all modeled baseline drug costs. This outcome was largely predicated on low resistance to fosfomycin. Conversely, ciprofloxacin was never the least costly option because of higher resistance and side effect cost, even if the drug cost was $0. We modeled 91% positive urine culture rate in postmenopausal women with dysuria; waiting for the urine culture prior to treatment would be the least costly strategy in a population with a predicted positive culture rate of <65%. CONCLUSION: The least costly strategy was empiric antibiotics with nitrofurantoin and trimethoprim/sulfamethoxazole, followed by waiting on culture results. Local resistance patterns will have an impact on cost minimization strategies. Empiric fosfomycin would be least costly with reduced drug costs, even at a level at which drug costs were higher than almost all other antibiotics. In a population with high posttest probability of positive urine culture, urinalysis adds unnecessary cost. Antibiotic stewardship programs should continue efforts to decrease fluoroquinolone use because of high resistance, side effects, and increased cost.
Asunto(s)
Antibacterianos/economía , Antibacterianos/uso terapéutico , Disuria/economía , Posmenopausia , Urinálisis/economía , Infecciones Urinarias/diagnóstico , Costos y Análisis de Costo , Árboles de Decisión , Combinación de Medicamentos , Femenino , Fosfomicina/economía , Fosfomicina/uso terapéutico , Humanos , Nitrofurantoína/economía , Nitrofurantoína/uso terapéutico , Sulfametizol/economía , Sulfametizol/uso terapéutico , Trimetoprim/economía , Trimetoprim/uso terapéutico , Infecciones Urinarias/tratamiento farmacológico , Infecciones Urinarias/microbiologíaAsunto(s)
Técnicas Bacteriológicas/normas , Servicio de Urgencia en Hospital/estadística & datos numéricos , Urinálisis/estadística & datos numéricos , Infecciones Urinarias/diagnóstico , Antibacterianos/uso terapéutico , Programas de Optimización del Uso de los Antimicrobianos , Técnicas Bacteriológicas/métodos , Humanos , Illinois , Urinálisis/economíaRESUMEN
AIM: Although a National Health Screening Program (NHSP) for chronic kidney disease (CKD) has been implemented in Korea since 2002, its cost-effectiveness has never been determined. This study aimed to estimate the cost-utility of NHSP for CKD in Korea. METHODS: A Markov decision analytic model was constructed to compare CKD screening strategies of the NHSP with no screening. We developed a model that simulated disease progression in a cohort aged 20-120 years or death from the societal perspective. RESULTS: Biannual screening starting at age 40 for CKD by proteinuria (dipstick) and estimated glomerular filtration ratio had an ICUR of $66 874/QALY relative to no screening. The targeted screening strategy had an ICUR of $37 812/QALY and $40 787/QALY for persons with diabetes and hypertension, respectively. ICURs improved with lower cost strategies. The most influential parameter that might make screening more cost-effective was the effectiveness of treatment on CKD to decrease disease progression and mortality. CONCLUSIONS: The Korean NHSP for CKD is more cost-effective for patients with diabetes or hypertension than the general population, consistent with prior studies. Although it is too early to conclude the cost-effectiveness of the Korean NHSP for CKD, this study provides evidence that is useful in evaluating the cost-effectiveness of CKD interventions.
Asunto(s)
Costos de la Atención en Salud , Tamizaje Masivo/economía , Programas Nacionales de Salud/economía , Insuficiencia Renal Crónica/diagnóstico , Insuficiencia Renal Crónica/economía , Adulto , Anciano , Anciano de 80 o más Años , Comorbilidad , Simulación por Computador , Análisis Costo-Beneficio , Nefropatías Diabéticas/diagnóstico , Nefropatías Diabéticas/economía , Nefropatías Diabéticas/epidemiología , Nefropatías Diabéticas/terapia , Femenino , Tasa de Filtración Glomerular , Humanos , Hipertensión/epidemiología , Masculino , Cadenas de Markov , Persona de Mediana Edad , Modelos Económicos , Valor Predictivo de las Pruebas , Pronóstico , Proteinuria/diagnóstico , Proteinuria/economía , Proteinuria/epidemiología , Proteinuria/terapia , Calidad de Vida , Años de Vida Ajustados por Calidad de Vida , Insuficiencia Renal Crónica/epidemiología , Insuficiencia Renal Crónica/terapia , República de Corea/epidemiología , Factores de Riesgo , Factores de Tiempo , Urinálisis/economía , Adulto JovenRESUMEN
Today, there is no reference method for the measurement of urinary proteins. The difficulties are that urine is a very complex biological fluid, and that there are a high intra-and inter-individual variability in the protein excretion rate. Progress has been made during the last thirty years, but high analytical variability persists among the colorimetric or turbidimetric methods used for urinary proteins measurement.
Asunto(s)
Proteinuria/diagnóstico , Urinálisis , Variación Biológica Individual , Biuret/química , Costos y Análisis de Costo , Estudios de Evaluación como Asunto , Humanos , Nefelometría y Turbidimetría/economía , Nefelometría y Turbidimetría/métodos , Nefelometría y Turbidimetría/normas , Proteinuria/economía , Proteinuria/orina , Pirogalol/química , Valores de Referencia , Colorantes de Rosanilina/química , Urinálisis/economía , Urinálisis/métodos , Urinálisis/normas , Urinálisis/tendencias , Toma de Muestras de Orina/normasRESUMEN
BACKGROUND: The technical advantages of direct-to-definitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) urine testing for monitoring patient compliance in pain management are well known. However, the design and implementation of LC-MS/MS methods are more controversial, including factors such as determining appropriate cutoffs, specimen processing (e.g., specimen hydrolysis), reporting of qualitative and/or quantitative results, and test menu. OBJECTIVES: The objective of the research was to compare the clinical performance of our previous urine pain toxicology panel, a combination of immunoassay (IA) screens and LC-MS/MS, to our current pain toxicology panel, which features direct-to-definitive LC-MS/MS for 34 drugs and metabolites. STUDY DESIGN: Six months of results from our previous pain toxicology panel were compared to 5.5 months of results from our current pain toxicology panel, enabling us to make conclusions regarding clinical performance. SETTING: The research took place at Brigham and Women's Hospital in Boston, MA. METHODS: The percentage of false positive IA results was evaluated for our previous pain toxicology panel. The positivity rates for each drug and/or metabolite were calculated for both the previous and current panels, including rates of detection of both prescribed and illicit drugs. The turnaround time (TAT), direct and send-out costs associated with each approach, as well as projected cost savings were also determined. RESULTS: False positive rates with IA ranged from 0% to 29%; the highest false positive rate was seen for 6-acetylmorphine (6-AM). The elimination of IA, addition of metabolites, and/or lowering of cutoffs increased the detection rate of 6-AM, benzoylecgonine (cocaine metabolite), fentanyl, morphine, and oxycodone. The ability to differentiate compliance from simulated compliance improved after eliminating specimen hydrolysis. The TAT improved significantly and projected yearly cost savings with the current panel was $95,003 (USD). In our opinion, qualitative results appeared sufficient to assess compliance in the majority of cases. LIMITATIONS: Our study was performed in a single academic center in a specific geographic region; therefore, our results may not be generalizable to other types of centers or regions. CONCLUSION: Direct-to-definitive LC-MS/MS testing has several clinical benefits, including reduction of false positive results, improved assessment of patient compliance, decreased TAT, and increased detection of drug use and abuse. Cost savings were also realized using this approach. KEY WORDS: Direct-to-definitive, LC-MS/MS, immunoassay, sensitivity, cost, pain management, turnaround time, patient compliance.